Cargando…

COVID-19 vaccination and venous thromboembolism risk in older veterans

INTRODUCTION: It is important for SARS-CoV-2 vaccine providers, vaccine recipients, and those not yet vaccinated to be well informed about vaccine side effects. We sought to estimate the risk of post-vaccination venous thromboembolism (VTE) to meet this need. METHODS: We conducted a retrospective co...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkin, Peter L., Brown, Steven H., Resendez, Skyler, McCray, Wilmon, Resnick, Melissa, Hall, Kendria, Franklin, Gillian, Connors, Jean M., Cushman, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052419/
https://www.ncbi.nlm.nih.gov/pubmed/37008615
http://dx.doi.org/10.1017/cts.2022.527
_version_ 1785015156250509312
author Elkin, Peter L.
Brown, Steven H.
Resendez, Skyler
McCray, Wilmon
Resnick, Melissa
Hall, Kendria
Franklin, Gillian
Connors, Jean M.
Cushman, Mary
author_facet Elkin, Peter L.
Brown, Steven H.
Resendez, Skyler
McCray, Wilmon
Resnick, Melissa
Hall, Kendria
Franklin, Gillian
Connors, Jean M.
Cushman, Mary
author_sort Elkin, Peter L.
collection PubMed
description INTRODUCTION: It is important for SARS-CoV-2 vaccine providers, vaccine recipients, and those not yet vaccinated to be well informed about vaccine side effects. We sought to estimate the risk of post-vaccination venous thromboembolism (VTE) to meet this need. METHODS: We conducted a retrospective cohort study to quantify excess VTE risk associated with SARS-CoV-2 vaccination in US veterans age 45 and older using data from the Department of Veterans Affairs (VA) National Surveillance Tool. The vaccinated cohort received at least one dose of a SARS-CoV-2 vaccine at least 60 days prior to 3/06/22 (N = 855,686). The control group was those not vaccinated (N = 321,676). All patients were COVID-19 tested at least once before vaccination with a negative test. The main outcome was VTE documented by ICD10-CM codes. RESULTS: Vaccinated persons had a VTE rate of 1.3755 (CI: 1.3752–1.3758) per thousand, which was 0.1 percent over the baseline rate of 1.3741 (CI: 1.3738–1.3744) per thousand in the unvaccinated patients, or 1.4 excess cases per 1,000,000. All vaccine types showed a minimal increased rate of VTE (rate of VTE per 1000 was 1.3761 (CI: 1.3754–1.3768) for Janssen; 1.3757 (CI: 1.3754–1.3761) for Pfizer, and for Moderna, the rate was 1.3757 (CI: 1.3748–1.3877)). The tiny differences in rates comparing either Janssen or Pfizer vaccine to Moderna were statistically significant (p < 0.001). Adjusting for age, sex, BMI, 2-year Elixhauser score, and race, the vaccinated group had a minimally higher relative risk of VTE as compared to controls (1.0009927 CI: 1.007673–1.0012181; p < 0.001). CONCLUSION: The results provide reassurance that there is only a trivial increased risk of VTE with the current US SARS-CoV-2 vaccines used in veterans older than age 45. This risk is significantly less than VTE risk among hospitalized COVID-19 patients. The risk-benefit ratio favors vaccination, given the VTE rate, mortality, and morbidity associated with COVID-19 infection.
format Online
Article
Text
id pubmed-10052419
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-100524192023-03-30 COVID-19 vaccination and venous thromboembolism risk in older veterans Elkin, Peter L. Brown, Steven H. Resendez, Skyler McCray, Wilmon Resnick, Melissa Hall, Kendria Franklin, Gillian Connors, Jean M. Cushman, Mary J Clin Transl Sci Research Article INTRODUCTION: It is important for SARS-CoV-2 vaccine providers, vaccine recipients, and those not yet vaccinated to be well informed about vaccine side effects. We sought to estimate the risk of post-vaccination venous thromboembolism (VTE) to meet this need. METHODS: We conducted a retrospective cohort study to quantify excess VTE risk associated with SARS-CoV-2 vaccination in US veterans age 45 and older using data from the Department of Veterans Affairs (VA) National Surveillance Tool. The vaccinated cohort received at least one dose of a SARS-CoV-2 vaccine at least 60 days prior to 3/06/22 (N = 855,686). The control group was those not vaccinated (N = 321,676). All patients were COVID-19 tested at least once before vaccination with a negative test. The main outcome was VTE documented by ICD10-CM codes. RESULTS: Vaccinated persons had a VTE rate of 1.3755 (CI: 1.3752–1.3758) per thousand, which was 0.1 percent over the baseline rate of 1.3741 (CI: 1.3738–1.3744) per thousand in the unvaccinated patients, or 1.4 excess cases per 1,000,000. All vaccine types showed a minimal increased rate of VTE (rate of VTE per 1000 was 1.3761 (CI: 1.3754–1.3768) for Janssen; 1.3757 (CI: 1.3754–1.3761) for Pfizer, and for Moderna, the rate was 1.3757 (CI: 1.3748–1.3877)). The tiny differences in rates comparing either Janssen or Pfizer vaccine to Moderna were statistically significant (p < 0.001). Adjusting for age, sex, BMI, 2-year Elixhauser score, and race, the vaccinated group had a minimally higher relative risk of VTE as compared to controls (1.0009927 CI: 1.007673–1.0012181; p < 0.001). CONCLUSION: The results provide reassurance that there is only a trivial increased risk of VTE with the current US SARS-CoV-2 vaccines used in veterans older than age 45. This risk is significantly less than VTE risk among hospitalized COVID-19 patients. The risk-benefit ratio favors vaccination, given the VTE rate, mortality, and morbidity associated with COVID-19 infection. Cambridge University Press 2023-02-01 /pmc/articles/PMC10052419/ /pubmed/37008615 http://dx.doi.org/10.1017/cts.2022.527 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Research Article
Elkin, Peter L.
Brown, Steven H.
Resendez, Skyler
McCray, Wilmon
Resnick, Melissa
Hall, Kendria
Franklin, Gillian
Connors, Jean M.
Cushman, Mary
COVID-19 vaccination and venous thromboembolism risk in older veterans
title COVID-19 vaccination and venous thromboembolism risk in older veterans
title_full COVID-19 vaccination and venous thromboembolism risk in older veterans
title_fullStr COVID-19 vaccination and venous thromboembolism risk in older veterans
title_full_unstemmed COVID-19 vaccination and venous thromboembolism risk in older veterans
title_short COVID-19 vaccination and venous thromboembolism risk in older veterans
title_sort covid-19 vaccination and venous thromboembolism risk in older veterans
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052419/
https://www.ncbi.nlm.nih.gov/pubmed/37008615
http://dx.doi.org/10.1017/cts.2022.527
work_keys_str_mv AT elkinpeterl covid19vaccinationandvenousthromboembolismriskinolderveterans
AT brownstevenh covid19vaccinationandvenousthromboembolismriskinolderveterans
AT resendezskyler covid19vaccinationandvenousthromboembolismriskinolderveterans
AT mccraywilmon covid19vaccinationandvenousthromboembolismriskinolderveterans
AT resnickmelissa covid19vaccinationandvenousthromboembolismriskinolderveterans
AT hallkendria covid19vaccinationandvenousthromboembolismriskinolderveterans
AT franklingillian covid19vaccinationandvenousthromboembolismriskinolderveterans
AT connorsjeanm covid19vaccinationandvenousthromboembolismriskinolderveterans
AT cushmanmary covid19vaccinationandvenousthromboembolismriskinolderveterans